Evidence map›Paper›PMID 23251222›Full record

ArticleClinical & developmental immunology2012

Fibronectin binding is required for acquisition of mesenchymal/endothelial differentiation potential in human circulating monocytes.

Noriyuki Seta, Yuka Okazaki, Keisuke Izumi, Hiroshi Miyazaki, Takashi Kato, Masataka Kuwana

Open access · goldAbstract read
In one paragraph

Article in Clinical & developmental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Noriyuki SetaDivision of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
Yuka Okazaki
Keisuke Izumi
Hiroshi Miyazaki
Takashi Kato
Masataka Kuwana
Keio University · JPKyowa Kirin (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously reported monocyte-derived multipotential cells (MOMCs), which include progenitors capable of differentiating into a variety of mesenchymal cells and endothelial cells. In vitro generation of MOMCs from circulating CD14(+) monocytes requires their binding to extracellular matrix (ECM) protein and exposure to soluble factor(s) derived from circulating CD14(-) cells. Here, we investigated the molecular factors involved in MOMC generation by examining the binding of monocytes to ECM proteins. We found that MOMCs were obtained on the fibronectin, but not on type I collagen, laminin, or poly-L-lysine. MOMC generation was followed by changes in the expression profiles of transcription factors and was completely inhibited by either anti-α(5) integrin antibody or a synthetic peptide that competed with the RGD domain for the β(1)-integrin binding site. These results indicate that acquisition of the multidifferentiation potential by circulating monocytes depends on their binding to the RGD domain of fibronectin via cell-surface α(5)β(1) integrin.

Indexed as

AdultBinding SitesCell DifferentiationCells, CulturedCollagen Type IEndothelial CellsExtracellular Matrix ProteinsFibronectinsHumansIntegrin alpha5beta1LamininLipopolysaccharide ReceptorsLysineMesenchymal Stem CellsMonocytesMultipotent Stem Cellsarginyl-glycyl-aspartic acidCollagen Type IExtracellular Matrix ProteinsFibronectinsIntegrin alpha5beta1LamininLipopolysaccharide ReceptorsLysineOligopeptidesTranscription Factors

Identifiers

PMID23251222
PMCPMC3509376
OpenAlexW1996616333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.